Angiotech/Bard
This article was originally published in The Gray Sheet
Executive Summary
Vancouver-based Angiotech Pharmaceuticals will continue development of paclitaxel-eluting Vascular Wrap after Bard opts out of a 1998 $30 mil. marketing agreement. Under the deal, Angiotech was responsible for only $10 mil. in development costs; the firm now maintains it can bring the device to market without the licensing fees, milestones and royalties it was to receive from Bard. The company recently announced the launch of a 60-patient Dutch feasibility trial for treating restenosis of the femoral and popliteal arteries after bypass grafting (1"The Gray Sheet" Jan. 13, 2003, p. 29)...